Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts

K Huhtinen, P Suvitie, J Hiissa, J Junnila, J Huvila, H Kujari, M Setälä, P Härkki, J Jalkanen, J Fraser, J Mäkinen, A Auranen, M Poutanen, A Perheentupa, K Huhtinen, P Suvitie, J Hiissa, J Junnila, J Huvila, H Kujari, M Setälä, P Härkki, J Jalkanen, J Fraser, J Mäkinen, A Auranen, M Poutanen, A Perheentupa

Abstract

Human epididymal secretory protein E4 (HE4, also known as WAP four-disulphide core domain protein 2) is a new promising biomarker for ovarian cancer but its specificity against ovarian endometriotic cysts is only superficially known. We, thus, analysed serum HE4 concentrations together with a tumour marker CA125 in serum samples of women diagnosed with various types of endometriosis, endometrial cancer or ovarian cancer, and in samples from healthy controls. The mean serum concentration of HE4 was significantly higher in serum samples of patients with both endometrial (99.2 pM, P<0.001) and ovarian (1125.4 pM, P<0.001) cancer but not with ovarian endometriomas (46.0 pM) or other types of endometriosis (45.5 pM) as compared with healthy controls (40.5 pM). The serum CA125 concentrations were elevated in patients with ovarian cancer, advanced endometriosis with peritoneal or deep lesions, or ovarian endometriomas, but not in the patients with endometrial cancer. The microarray results revealed that the mRNA expression of the genes encoding HE4 and CA125 reflected the serum protein concentrations. Taken together, measuring both HE4 and CA125 serum concentrations increases the accuracy of ovarian cancer diagnosis and provides valuable information to discriminate ovarian tumours from ovarian endometriotic cysts.

Figures

Figure 1
Figure 1
Correlation between serum HE4 (pM) and CA125 (U ml−1) concentrations as ln-transformation in patients with ovarian endometriosis (Ovarian endo, ○), ovarian cancer (OvCa, •), endometrial cancer (EmCa, ▴), and controls (ctrl, X). The broken lines show the threshold values for positive diagnosis of CA125 (35 U ml−1) and HE4 (70 pM, according to Moore et al (2008a)).

References

    1. (1997) Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 67: 817–821
    1. Benedet JL, Bender H, Jones 3rd H, Ngan HY, Pecorelli S (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers, FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70: 209–262
    1. Drapkin R, von Horsten H, Lin Y, Mok S, Crum C, Welch W, Hecht J (2005) Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65: 2162–2169
    1. Gagnon A, Ye B (2008) Discovery and application of protein biomarkers for ovarian cancer. Curr Opin Obstet Gynecol 20: 9–13
    1. Galgano M, Hampton G, Frierson HJ (2006) Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 19: 847–853
    1. Giudice L, Kao L (2004) Endometriosis. Lancet 364: 1789–1799
    1. Havrilesky L, Whitehead C, Rubatt J, Cheek R, Groelke J, He Q, Malinowski D, Fischer T, Berchuck A (2008) Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 110: 374–382
    1. Hellström I, Hellström K (2008) SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol 622: 15–21
    1. Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter J, Schummer M, McIntosh M, Drescher C, Urban N, Hellström K (2003) The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 63: 3695–3700
    1. Kitawaki J, Ishihara H, Koshiba H, Kiyomizu M, Teramoto M, Kitaoka Y, Honjo H (2005) Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas. Hum Reprod 20: 1999–2003
    1. Lowe KA, Shah C, Wallace E, Anderson G, Paley P, McIntosh M, Andersen MR, Scholler N, Bergan L, Thorpe J, Urban N, Drescher CW (2008) Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 17: 2480–2487
    1. Markman M (1997) The role of CA-125 in the management of ovarian cancer. Oncologist 2: 6–9
    1. Mol B, Bayram N, Lijmer J, Wiegerinck M, Bongers M, van der Veen F, Bossuyt P (1998) The performance of CA-125 measurement in the detection of endometriosis: a meta-analysis. Fertil Steril 70: 1101–1108
    1. Moore R, Brown A, Miller M, Badgwell D, Lu Z, Allard W, Granai C, Bast RJ, Lu K (2008b) Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 110: 196–201
    1. Moore R, Brown A, Miller M, Skates S, Allard W, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai C, Bast RJ (2008a) The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108: 402–408
    1. Moore R, McMeekin D, Brown A, DiSilvestro P, Miller M, Allard W, Gajewski W, Kurman R, Bast RJ, Skates S (2009) A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112: 40–46
    1. Nagle C, Olsen C, Webb P, Jordan S, Whiteman D, Green A (2008) Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors. Eur J Cancer 44: 2477–2484
    1. Ness R (2003) Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 189: 280–294
    1. Nisolle M, Donnez J (1997) Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. Fertil Steril 68: 585–596
    1. Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, Noguchi M (2000) Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 60: 7052–7056
    1. Seeber B, Sammel M, Fan X, Gerton G, Shaunik A, Chittams J, Barnhart K (2008) Panel of markers can accurately predict endometriosis in a subset of patients. Fertil Steril 89: 1073–1081
    1. Terry K, Sluss P, Skates S, Mok S, Ye B, Vitonis A, Cramer D (2004) Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers 20: 53–70

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi